Clinical Study
Etiologies and Treatment Burden in Adult Patients with Pure Red Cell Aplasia: A Single-Center Experience and Review of Literature
Table 1
Causes and treatment outcomes of adult patients with PRCA.
| | Cause of PRCA/gender | Median time to develop PRCA from diagnosis/treatment (Mo) | Treatment (N) | Response rate within 2 Mo (%) | Median number of PRCT | Time to hematologic recovery (wk) | Relapse rate (%) |
| | Erythropoietin/F:M = 9 : 6 | 10 (5–21) | Immunosuppressant (N = 4) | 0 | 27 (8–50) | 52 (40–64) | 0 | | Other therapies (N = 4) | 0 | 14 (8–32) | 13 (12–14) | 0 | | Supportive treatment (N = 8) | — | 40 (34–52) | 68 (52–72) | 0 |
| | Parvovirus B19 infection: | | (i) HIV infection/F:M = 0 : 3 | 6 (0–10) | IvIg (N = 3) | 100 | 4 (2–6) | 3 (3–4) | 0 | | (ii) Kidney transplantation/F:M = 1 : 2 | 4 (1–5) | IvIg (N = 3) | 100 | 4 (4–5) | 4 (3–12) | 0 |
| | Thymoma/F:M = 3 : 1 | 3.5 (0–36) | Thymectomy (N = 1, type B3) | 0 | 100 | — | — | | Chemotherapy and immunosuppressive therapy (N = 3, type B1 = 2, B3 = 1) | 0 | 30 (20–50) | 31 (28–34) | 0 | | Thymectomy/chemotherapy (N = 0) | — | — | — | — |
| | Zidovudine (AZT)/F:M = 1 : 1 | 84 (48–120) | Cessation of AZT (N = 2) | 100 | 30 (10–50) | 3.5 (3–4) | 0 |
| | Primary autoimmune PRCA/F:M = 2 : 0 | — | IvIg (N = 2) | 100 | 8 (6–10) | 5 (4–6) | 50 |
| | Systemic lupus nephritis/F:M = 1 : 0 | 156 | Cellcept/danazol/pred/Mabthera | 0 | 30 | 132 | 0 |
| | Kaposi sarcoma/F:M = 0 : 1 | 60 | Chemotherapy | 0 | 6 | 12 | 0 |
| | Transplant (ABO mismatch)/F:M = 1 : 0 | 4 | Cyclosporin A/rEPO/Androlic/Velcade | 0 | 75 | 104 | 0 |
|
|
